BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 35579975)

  • 21. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage.
    Yu L; Jiang M; Qu P; Wu Z; Sun P; Xi M; Qin Y; Liu X; Liao G; Lei X; Sun L; Zhang Y; Li Z; Chen W; Qiao YL
    Int J Cancer; 2018 Aug; 143(4):813-822. PubMed ID: 29524206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of the HPV E6/E7 mRNA Aptima HPV assay combined with partial genotyping compared with the HPV DNA Cobas 4800 HPV test for use in primary screening: Results from the CERVIVA HPV primary screening study in Ireland.
    White C; Reynolds S; Murphy K; Keegan H; Naik P; O'Brien R; Pilkington L; Sharkey Ochoa I; Glesson G; Russell N; Nuttall D; Tewari P; Wright F; O'Toole S; Sharp L; Flannelly G; O'Leary JJ; Martin CM;
    Int J Cancer; 2024 Jan; 154(1):53-64. PubMed ID: 37632406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Different HPV-based Strategies and Cytology in Routine Cervical Cancer Screening Programme in China: A Population-based Study.
    Wang S; Li L; Yang J; Han N; Bao H; Wang HJ
    Cancer Prev Res (Phila); 2022 Jan; 15(1):45-54. PubMed ID: 34556493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme.
    Zappacosta R; Caraceni D; Ciccocioppo L; Rotondo T; Capanna S; Gatta DM; D'Angelo C; Rosini S
    Gynecol Oncol; 2013 Mar; 128(3):427-32. PubMed ID: 23200910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of addition of HPV DNA testing to the cytology based cervical cancer screening and triage of findings with p16/Ki67 immunocytochemistry staining in 35 and 45 years old women LIBUSE trial data analysis.
    Sláma J; Dvořák V; Trnková M; Skřivánek A; Hurdálková K; Ovesná P; Nováčková M
    Ceska Gynekol; 2020; 85(6):368-374. PubMed ID: 33711896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of human papillomavirus E6/E7 mRNA assay for primary cervical cancer screening and triage: Population-based screening in China.
    Zhang J; Yang D; Cui X; Liu G; Cui Z; Wang C; Piao H
    Front Cell Infect Microbiol; 2022; 12():935071. PubMed ID: 36105144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system.
    Zappacosta R; Gatta DM; Marinucci P; Capanna S; Lattanzio G; Caraceni D; Rosini S
    Expert Rev Mol Diagn; 2015 Jan; 15(1):137-50. PubMed ID: 25245757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.
    Wentzensen N; Fetterman B; Castle PE; Schiffman M; Wood SN; Stiemerling E; Tokugawa D; Bodelon C; Poitras N; Lorey T; Kinney W
    J Natl Cancer Inst; 2015 Dec; 107(12):djv257. PubMed ID: 26376685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology.
    Wang J; Dong J; Zhou Y; Wang K; Pan M; Deng Z; Wang P; Du Y; Lu W
    Gynecol Oncol; 2022 Mar; 164(3):607-614. PubMed ID: 34996586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of p16
    Song F; Belinson JL; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    Gynecol Oncol; 2021 Aug; 162(2):322-330. PubMed ID: 34059349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women.
    Yao YL; Tian QF; Cheng B; Cheng YF; Ye J; Lu WG
    J Zhejiang Univ Sci B; 2017 Mar.; 18(3):256-262. PubMed ID: 28271661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV genotyping for triage of women with abnormal cervical cancer screening results: a multicenter prospective study.
    Nakamura Y; Matsumoto K; Satoh T; Nishide K; Nozue A; Shimabukuro K; Endo S; Nagai K; Oki A; Ochi H; Morishita Y; Noguchi M; Yoshikawa H
    Int J Clin Oncol; 2015 Oct; 20(5):974-81. PubMed ID: 25652908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of p16/Ki-67 dual-stain as triage test for high-risk HPV-positive women: A hospital-based cross-sectional study.
    Chen X; Chen C; Liu L; Dai W; Zhang J; Han C; Zhou S
    Cancer Cytopathol; 2022 Dec; 130(12):955-963. PubMed ID: 35852302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
    Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
    Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.